A 39-year-old man is admitted to the hospital with profuse diarrhea. His wife says that it started yesterday and since then the patient has passed over 15 liters of watery stools which have become progressively clear and odorless. Over the past 2 days, the patient has only eaten homemade food. His wife and daughter do not have any symptoms. His wife says that he returned from a trip to rural India 2 days before the symptoms began. He has a history of gastroesophageal reflux disease. His vitals are as follows: blood pressure 95/70 mm Hg, heart rate 100/min, respiratory rate 21/min, and temperature 35.8°C (96.4°F). The patient appears fatigued and pale. His skin elasticity and turgor are decreased. Cardiac auscultation reveals a holosystolic murmur that changes characteristics with changes in the patient’s position. The chronic intake of which of the following drugs could predispose the patient to this condition?
Q62
A 62-year-old woman with no significant past medical history presents with progressive dyspnea on exertion over the past 6 months. Echocardiogram reveals elevated pulmonary artery pressure (PAP) of 55 mmHg with normal left ventricular ejection fraction and no evidence of left-sided valvular disease. Right heart catheterization confirms mean PAP of 50 mmHg with pulmonary capillary wedge pressure of 10 mmHg. Intraoperative administration of intravenous adenosine causes the PAP to decrease to 35 mmHg. What pharmacological therapy is most likely to provide long-term benefit for this patient?
Q63
A 50-year-old man comes to the physician for his annual health maintenance examination. The patient feels well. He has a history of hypertension, for which he currently takes lisinopril. He has smoked a pack of cigarettes daily for 20 years. He drinks 5–6 beers on weekends. He is 181 cm tall (5 ft 11 in), weighs 80 kg (176.4 lbs); BMI is 24.6 kg/m2. His pulse is 75/min, blood pressure is 140/85 mm Hg, and respirations are 18/min. Physical examination is unremarkable. Laboratory studies show:
Total cholesterol 263 mg/dL
High-density lipoprotein cholesterol 36 mg/dL
Triglycerides 180 mg/dL
In addition to dietary and lifestyle modification, administration of which of the following agents is the most appropriate next step in management?
Q64
A 51-year-old woman presents to the emergency department with a 2-day history of bilateral lower extremity swelling. She says that her legs do not hurt, but she noticed she was gaining weight and her legs were becoming larger. Her past medical history is significant for morbid obesity, hypertension, and hypercholesterolemia. She says the swelling started after she was recently started on a new medication to help her blood pressure, but she does not remember the name of the medication. Which of the following is most likely the mechanism of action for the drug that was prescribed to this patient?
Q65
A 70-year-old man presents to his primary care physician for a general checkup. He states that he has been doing well and taking his medications as prescribed. He recently started a new diet and supplement to improve his health and has started exercising. The patient has a past medical history of diabetes, a myocardial infarction, and hypertension. He denies any shortness of breath at rest or with exertion. An ECG is performed and is within normal limits. Laboratory values are ordered as seen below.
Serum:
Na+: 139 mEq/L
Cl-: 100 mEq/L
K+: 6.7 mEq/L
HCO3-: 25 mEq/L
Glucose: 133 mg/dL
Ca2+: 10.2 mg/dL
Which of the following is the most likely cause of this patient's presentation?
Q66
A 69-year-old man with hypertension and congestive heart failure is brought to the emergency department because of a 9-day history of worsening shortness of breath and swelling of his legs. His respirations are 25/min, and blood pressure is 160/98 mm Hg. Pulse oximetry on 5 L O2 via nasal cannula shows an oxygen saturation of 92%. Examination shows 2+ pretibial edema bilaterally. Crackles are heard at both lung bases. ACE inhibitors are being considered for this patient's treatment. The enzyme that these medications inhibit, which is responsible for bradykinin breakdown, is primarily produced in which of the following?
Q67
A 70-year-old man with a history of poorly controlled congestive heart failure comes to the physician for a follow-up examination. At his previous visit 4 months ago, a new drug was added to his treatment regimen. He reports that his dyspnea and peripheral edema have improved. His pulse is 70/min and blood pressure is 110/80 mm Hg. Physical examination shows bilateral, mildly tender enlargement of breast tissue. This patient's physical examination finding is most likely caused by a drug that acts at which of the following sites in the kidney?
Q68
A 42-year-old man presents to his primary care physician for preventative care. He does not have any current complaint. His father died of diabetic nephropathy. Vital signs include a temperature of 36.7°C (98.06°F), blood pressure of 150/95 mm Hg, and pulse of 90/min. His fasting blood glucose is 159 mg/dL (on 2 occasions) and HbA1c is 8.1%. The patient is started on metformin and lifestyle modifications. 3 months later, he comes for a follow-up visit. His serum blood glucose is 370 mg/dL and HbA1C is 11%. The patient currently complains of weight loss and excessive urination. Which of the following is the optimal therapy for this patient?
Q69
A 63-year-old woman presents with dyspnea on exertion. She reports that she used to work in her garden without any symptoms, but recently she started to note dyspnea and fatigue after working for 20–30 minutes. She has type 2 diabetes mellitus diagnosed 2 years ago but she does not take any medications preferring natural remedies. She also has arterial hypertension and takes torsemide 20 mg daily. The weight is 88 kg and the height is 164 cm. The vital signs include: blood pressure is 140/85 mm Hg, heart rate is 90/min, respiratory rate is 14/min, and the temperature is 36.6℃ (97.9℉). Physical examination is remarkable for increased adiposity, pitting pedal edema, and present S3. Echocardiography shows a left ventricular ejection fraction of 51%. The combination of which of the following medications would be a proper addition to the patient’s therapy?
Q70
A 58-year-old man is rushed to the ER in the middle of the night with severe chest pain. He arrives in the ER short of breath, sweating, and looking terrified. His blood pressure is noted to be 250/140, and he is immediately administered nitroprusside. His blood pressure is controlled, but he soon develops confusion and lactic acidosis. Which of the following best explains these findings?
Antihypertensives US Medical PG Practice Questions and MCQs
Question 61: A 39-year-old man is admitted to the hospital with profuse diarrhea. His wife says that it started yesterday and since then the patient has passed over 15 liters of watery stools which have become progressively clear and odorless. Over the past 2 days, the patient has only eaten homemade food. His wife and daughter do not have any symptoms. His wife says that he returned from a trip to rural India 2 days before the symptoms began. He has a history of gastroesophageal reflux disease. His vitals are as follows: blood pressure 95/70 mm Hg, heart rate 100/min, respiratory rate 21/min, and temperature 35.8°C (96.4°F). The patient appears fatigued and pale. His skin elasticity and turgor are decreased. Cardiac auscultation reveals a holosystolic murmur that changes characteristics with changes in the patient’s position. The chronic intake of which of the following drugs could predispose the patient to this condition?
A. Ibuprofen
B. Aspirin
C. Pantoprazole (Correct Answer)
D. Levocetirizine
E. Propranolol
Explanation: ***Pantoprazole***
- The patient presents with classic symptoms of **cholera**, including rapid onset of **voluminous, watery, odorless stools** after returning from an endemic area (rural India).
- **Proton pump inhibitors (PPIs)** like pantoprazole reduce stomach acidity, which can lower the infectious dose of *Vibrio cholerae* required to cause disease, thereby increasing susceptibility.
*Ibuprofen*
- **NSAIDs** like ibuprofen primarily inhibit prostaglandin synthesis, which can cause gastrointestinal side effects such as gastritis, ulcers, and bleeding.
- They do not directly predispose to cholera infection by altering gastric pH or affecting bacterial colonization.
*Aspirin*
- **Aspirin**, an NSAID and antiplatelet agent, can cause gastrointestinal irritation and bleeding, especially at high doses.
- It does not significantly alter gastric pH in a way that would predispose to cholera beyond general stomach upset, nor does it affect immune response to enteric pathogens.
*Levocetirizine*
- **Levocetirizine** is an antihistamine used for allergic conditions.
- It has no known effect on gastric acidity or susceptibility to gastrointestinal infections like cholera.
*Propranolol*
- **Propranolol** is a beta-blocker used for conditions like hypertension, angina, and anxiety.
- It does not affect gastric pH or the immune response to enteric pathogens, and therefore, does not predispose to cholera.
Question 62: A 62-year-old woman with no significant past medical history presents with progressive dyspnea on exertion over the past 6 months. Echocardiogram reveals elevated pulmonary artery pressure (PAP) of 55 mmHg with normal left ventricular ejection fraction and no evidence of left-sided valvular disease. Right heart catheterization confirms mean PAP of 50 mmHg with pulmonary capillary wedge pressure of 10 mmHg. Intraoperative administration of intravenous adenosine causes the PAP to decrease to 35 mmHg. What pharmacological therapy is most likely to provide long-term benefit for this patient?
A. Amlodipine (Correct Answer)
B. Bosentan
C. Epoprostenol
D. Sildenafil
E. Adenosine
Explanation: ***Amlodipine***
- The patient has **idiopathic pulmonary arterial hypertension (PAH, Group 1 PH)** confirmed by elevated mean PAP >20 mmHg with normal pulmonary capillary wedge pressure (≤15 mmHg), excluding left heart disease.
- The **positive acute vasodilator response** (PAP drop >10 mmHg to <40 mmHg) during right heart catheterization indicates **vasoreactivity**, which predicts favorable response to **calcium channel blockers (CCBs)**.
- **Amlodipine** or other CCBs (nifedipine, diltiazem) are the **first-line long-term therapy** for vasoreactive idiopathic PAH, with some patients achieving near-normalization of PAP.
- Only about **10% of idiopathic PAH patients** are vasoreactive, making this finding clinically significant.
*Bosentan*
- **Bosentan** is an **endothelin receptor antagonist** used for **PAH (Group 1)**.
- While effective for PAH, it is typically reserved for patients who are **non-vasoreactive** or who fail CCB therapy.
- Given this patient's positive vasodilator response, a **CCB trial is preferred first** due to better long-term outcomes in vasoreactive patients.
*Epoprostenol*
- **Epoprostenol** is a **prostacyclin analog** used for severe **PAH**, particularly WHO functional class III-IV.
- It requires **continuous intravenous infusion** and is reserved for more advanced or refractory PAH.
- Not appropriate as **first-line therapy** in a vasoreactive patient who can be treated with oral CCBs.
*Sildenafil*
- **Sildenafil** is a **phosphodiesterase-5 inhibitor** effective for **PAH**.
- Like bosentan, it is used for patients who are **non-vasoreactive** or have failed CCB therapy.
- In a vasoreactive patient, **CCBs are preferred** due to superior long-term outcomes in this subset.
*Adenosine*
- **Adenosine** is an **ultrashort-acting vasodilator** used as a **diagnostic agent** during right heart catheterization to assess vasoreactivity.
- It has a half-life of seconds and is **not suitable for long-term therapy**.
- Alternative agents for vasoreactivity testing include inhaled nitric oxide and intravenous epoprostenol.
Question 63: A 50-year-old man comes to the physician for his annual health maintenance examination. The patient feels well. He has a history of hypertension, for which he currently takes lisinopril. He has smoked a pack of cigarettes daily for 20 years. He drinks 5–6 beers on weekends. He is 181 cm tall (5 ft 11 in), weighs 80 kg (176.4 lbs); BMI is 24.6 kg/m2. His pulse is 75/min, blood pressure is 140/85 mm Hg, and respirations are 18/min. Physical examination is unremarkable. Laboratory studies show:
Total cholesterol 263 mg/dL
High-density lipoprotein cholesterol 36 mg/dL
Triglycerides 180 mg/dL
In addition to dietary and lifestyle modification, administration of which of the following agents is the most appropriate next step in management?
A. Peroxisome proliferator-activated receptor alpha activator
B. Proprotein convertase subtilisin kexin 9 inhibitor
C. Bile acid resins
D. HMG-CoA reductase inhibitor (Correct Answer)
E. Cholesterol absorption inhibitor
Explanation: ***HMG-CoA reductase inhibitor***
- This patient has multiple **cardiovascular risk factors** (hypertension, smoking, low HDL, elevated LDL-c calculated from total cholesterol and triglycerides) and elevated LDL-c. An **HMG-CoA reductase inhibitor (statin)** is the first-line pharmacotherapy in such cases to reduce the risk of atherosclerotic cardiovascular disease events.
- Statins effectively lower **LDL-c**, which is the primary target for cholesterol reduction in patients at high risk for cardiovascular disease.
*Peroxisome proliferator-activated receptor alpha activator*
- **Fibrates** (PPAR-α activators) are primarily used to lower **triglycerides** and increase HDL, and are not the first-line choice for lowering elevated LDL-c in high-risk patients.
- They are typically reserved for severe hypertriglyceridemia not controlled by statins, or in patients intolerant to statins whose primary lipid issue is hypertriglyceridemia.
*Proprotein convertase subtilisin kexin 9 inhibitor*
- **PCSK9 inhibitors** are potent LDL-c lowering agents, but they are typically used as **adjunctive therapy** in patients with high cardiovascular risk who have not achieved adequate LDL-c reduction with maximum tolerated statin therapy, or in patients with familial hypercholesterolemia.
- Given that this patient has not yet started statin therapy, a PCSK9 inhibitor is not the initial treatment strategy.
*Bile acid resins*
- **Bile acid resins** (e.g., cholestyramine) lower LDL-c by binding to bile acids in the intestine, but they are **less effective** than statins and can sometimes increase triglycerides.
- They are generally not the first-line choice for primary LDL-c reduction due to their side effect profile (e.g., GI upset) and lower efficacy compared to statins.
*Cholesterol absorption inhibitor*
- **Ezetimibe** (a cholesterol absorption inhibitor) reduces cholesterol absorption in the small intestine, leading to lower LDL-c.
- It is often used as an **add-on therapy** to statins or as monotherapy in statin-intolerant patients, but not as the initial drug of choice when a statin is indicated and tolerated.
Question 64: A 51-year-old woman presents to the emergency department with a 2-day history of bilateral lower extremity swelling. She says that her legs do not hurt, but she noticed she was gaining weight and her legs were becoming larger. Her past medical history is significant for morbid obesity, hypertension, and hypercholesterolemia. She says the swelling started after she was recently started on a new medication to help her blood pressure, but she does not remember the name of the medication. Which of the following is most likely the mechanism of action for the drug that was prescribed to this patient?
A. Potassium-sparing diuretic
B. Inhibition of calcium channels (Correct Answer)
C. Inhibition of enzyme in the lung
D. Potassium-wasting diuretic
E. Inhibition of hormone receptor
Explanation: ***Inhibition of calcium channels***
- The patient's presentation of **bilateral lower extremity swelling** (peripheral edema) after starting a new blood pressure medication is a classic side effect of **calcium channel blockers (CCBs)**, particularly dihydropyridine CCBs like amlodipine.
- CCBs cause **vasodilation of arterioles**, leading to increased hydrostatic pressure in the capillaries and subsequent fluid extravasation into the interstitial space.
*Potassium-sparing diuretic*
- **Potassium-sparing diuretics** primarily work in the collecting duct to increase sodium excretion and retain potassium, without causing or significantly worsening peripheral edema.
- They are used to treat hypertension and heart failure, but their mechanism does not directly cause dependent edema in the way described.
*Inhibition of enzyme in the lung*
- This description most closely refers to the **angiotensin-converting enzyme (ACE)**, which is inhibited by ACE inhibitors used for hypertension.
- **ACE inhibitors** typically do not cause peripheral edema; their common side effects include cough and angioedema (though less common).
*Potassium-wasting diuretic*
- **Potassium-wasting diuretics** (e.g., loop or thiazide diuretics) increase urine output and are used to *reduce* fluid retention and swelling, not cause it.
- While they can lower blood pressure, they would alleviate, rather than induce, bilateral lower extremity swelling.
*Inhibition of hormone receptor*
- This mechanism could refer to several classes of antihypertensives, such as **beta-blockers** (inhibiting adrenergic receptors) or **angiotensin receptor blockers (ARBs)** (inhibiting angiotensin II receptors).
- Neither beta-blockers nor ARBs are typically associated with prominent bilateral lower extremity swelling as a common side effect.
Question 65: A 70-year-old man presents to his primary care physician for a general checkup. He states that he has been doing well and taking his medications as prescribed. He recently started a new diet and supplement to improve his health and has started exercising. The patient has a past medical history of diabetes, a myocardial infarction, and hypertension. He denies any shortness of breath at rest or with exertion. An ECG is performed and is within normal limits. Laboratory values are ordered as seen below.
Serum:
Na+: 139 mEq/L
Cl-: 100 mEq/L
K+: 6.7 mEq/L
HCO3-: 25 mEq/L
Glucose: 133 mg/dL
Ca2+: 10.2 mg/dL
Which of the following is the most likely cause of this patient's presentation?
A. Medication (Correct Answer)
B. Acute renal failure
C. Hemolysis
D. Dietary changes
E. Rhabdomyolysis
Explanation: ***Medication***
- The patient's **hyperkalemia** (K+ 6.7 mEq/L) despite feeling well, suggests a common side effect of medications, particularly those used for his pre-existing conditions like **hypertension** (**ACE inhibitors**, **ARBs**, **spironolactone**) and **diabetes**.
- Medications are a frequent cause of asymptomatic electrolyte abnormalities, and given his complex medical history and the absence of acute symptoms, this is the most likely culprit.
*Acute renal failure*
- While acute renal failure can cause **hyperkalemia**, it typically presents with other symptoms such as **oliguria**, **fluid retention**, or other signs of organ dysfunction, which are not described.
- The patient is reported to be "doing well" without **shortness of breath** or other acute complaints, making acute renal failure less likely as the primary cause of isolated hyperkalemia.
*Hemolysis*
- **Hemolysis** can release intracellular potassium, leading to **pseudohyperkalemia**, but it would typically be suspected in cases of **blood draw errors** or conditions causing red blood cell breakdown, none of which are indicated.
- The patient's presentation does not include any signs or symptoms suggestive of red cell destruction.
*Dietary changes*
- While an extremely **high-potassium diet** or certain **supplements** could contribute to hyperkalemia, it is less common for dietary changes alone to cause such a significant elevation in a patient with normal organ function.
- Given his medical history, medication-induced hyperkalemia is a more direct and common explanation.
*Rhabdomyolysis*
- **Rhabdomyolysis** involves the breakdown of muscle tissue, releasing potassium and other intracellular contents, but it is usually associated with significant **muscle pain**, **weakness**, and elevated **creatine kinase**.
- The patient denies these symptoms and has no other indicators pointing towards severe muscle injury.
Question 66: A 69-year-old man with hypertension and congestive heart failure is brought to the emergency department because of a 9-day history of worsening shortness of breath and swelling of his legs. His respirations are 25/min, and blood pressure is 160/98 mm Hg. Pulse oximetry on 5 L O2 via nasal cannula shows an oxygen saturation of 92%. Examination shows 2+ pretibial edema bilaterally. Crackles are heard at both lung bases. ACE inhibitors are being considered for this patient's treatment. The enzyme that these medications inhibit, which is responsible for bradykinin breakdown, is primarily produced in which of the following?
A. Pulmonary endothelium (Correct Answer)
B. Atria
C. Juxtaglomerular cells
D. Zona glomerulosa
E. Liver
Explanation: ***Pulmonary endothelium***
- The **pulmonary endothelium** is rich in **angiotensin-converting enzyme (ACE)**, which is responsible for the breakdown of **bradykinin**.
- Medications like **ACE inhibitors** block this enzyme, leading to increased bradykinin levels, which can cause side effects like **cough** and **angioedema**.
*Atria*
- The **atria** produce **atrial natriuretic peptide (ANP)** in response to stretch, which plays a role in fluid and electrolyte balance but not directly in bradykinin breakdown.
- ANP promotes **vasodilation** and **natriuresis**, contributing to blood pressure regulation.
*Juxtaglomerular cells*
- **Juxtaglomerular cells** in the kidney produce **renin**, an enzyme that initiates the **renin-angiotensin-aldosterone system** by converting angiotensinogen to angiotensin I.
- Renin production is stimulated by reduced renal perfusion pressure, sympathetic activity, and decreased sodium delivery to the macula densa.
*Zona glomerulosa*
- The **zona glomerulosa** of the adrenal cortex produces **aldosterone**, a mineralocorticoid that regulates sodium and potassium balance.
- Aldosterone's primary role is in salt and water retention, and it does not directly participate in bradykinin metabolism.
*Liver*
- The **liver** is involved in the synthesis of many plasma proteins, clotting factors, and detoxification processes, but it is not the primary site for bradykinin breakdown.
- While the liver metabolizes many substances, **ACE activity** for bradykinin degradation is concentrated in the pulmonary endothelium.
Question 67: A 70-year-old man with a history of poorly controlled congestive heart failure comes to the physician for a follow-up examination. At his previous visit 4 months ago, a new drug was added to his treatment regimen. He reports that his dyspnea and peripheral edema have improved. His pulse is 70/min and blood pressure is 110/80 mm Hg. Physical examination shows bilateral, mildly tender enlargement of breast tissue. This patient's physical examination finding is most likely caused by a drug that acts at which of the following sites in the kidney?
A. Cortical collecting duct (Correct Answer)
B. Thick ascending limb
C. Early distal convoluted tubule
D. Efferent arteriole
E. Juxtaglomerular apparatus
Explanation: ***Cortical collecting duct***
- The patient's symptoms of improved dyspnea and peripheral edema, along with **gynecomastia**, strongly suggest the use of **spironolactone**.
- Spironolactone is an **aldosterone antagonist** that acts on the mineralocorticoid receptors in the **cortical collecting duct**, leading to increased sodium and water excretion and potassium retention, while also causing gynecomastia as a common side effect.
*Thick ascending limb*
- Medications acting here are **loop diuretics** (e.g., furosemide), which are potent diuretics but do not typically cause gynecomastia.
- While loop diuretics improve heart failure symptoms, they do not explain the **tender breast enlargement**.
*Early distal convoluted tubule*
- **Thiazide diuretics** (e.g., hydrochlorothiazide) act at this site, inhibiting sodium and chloride reabsorption.
- Thiazides improve heart failure symptoms but are not associated with **gynecomastia**.
*Efferent arteriole*
- Medications that act on the efferent arteriole (e.g., **ACE inhibitors** and **ARBs**) can improve heart failure, but they do not typically cause gynecomastia.
- These drugs primarily reduce afterload and preload, and prevent cardiac remodeling.
*Juxtaglomerular apparatus*
- The juxtaglomerular apparatus is involved in **renin secretion**, which is regulated by beta-blockers or direct renin inhibitors.
- While these drugs are used in heart failure, they do not cause **gynecomastia**.
Question 68: A 42-year-old man presents to his primary care physician for preventative care. He does not have any current complaint. His father died of diabetic nephropathy. Vital signs include a temperature of 36.7°C (98.06°F), blood pressure of 150/95 mm Hg, and pulse of 90/min. His fasting blood glucose is 159 mg/dL (on 2 occasions) and HbA1c is 8.1%. The patient is started on metformin and lifestyle modifications. 3 months later, he comes for a follow-up visit. His serum blood glucose is 370 mg/dL and HbA1C is 11%. The patient currently complains of weight loss and excessive urination. Which of the following is the optimal therapy for this patient?
A. A thiazolidinedione added to metformin
B. Basal-bolus insulin (Correct Answer)
C. Basal insulin added to metformin
D. A sulfonylurea added to metformin
E. A sodium-glucose cotransporter 2 inhibitor added to metformin
Explanation: ***Basal-bolus insulin***
- This patient presents with an HbA1C of 11% and symptoms of **polyuria** and **weight loss**, indicating significant hyperglycemia. Due to the high HbA1c and symptomatic presentation despite initial metformin and lifestyle modifications, **aggressive glucose lowering** is required to prevent acute complications and long-term organ damage.
- Basal-bolus insulin therapy provides both continuous basal insulin to control fasting glucose and prandial boluses to manage post-meal glucose spikes, offering the most comprehensive and effective glucose control in severe hyperglycemia.
*A thiazolidinedione added to metformin*
- Thiazolidinediones (TZDs) like pioglitazone improve insulin sensitivity and are used as a second-line agent, but they have a **slow onset of action** and are generally insufficient for patients with such severe hyperglycemia (HbA1c 11%).
- TZDs can take several weeks to reach maximal effect and are not potent enough for immediate and significant glucose reduction in symptomatic patients with markedly elevated HbA1c.
*Basal insulin added to metformin*
- While adding basal insulin to metformin is a common step for patients whose HbA1c is a few points above target, an HbA1c of 11% with symptoms of weight loss and polyuria indicates **more severe insulin deficiency** or resistance requiring more comprehensive insulin replacement.
- Basal insulin alone would not adequately address post-prandial hyperglycemia, which is likely contributing significantly to the overall high HbA1c.
*A sulfonylurea added to metformin*
- Sulfonylureas stimulate insulin release from pancreatic beta cells, but their efficacy is limited, and they carry a risk of **hypoglycemia** and weight gain.
- Given the patient's very high HbA1c of 11%, sulfonylureas would likely be insufficient to achieve target glycemic control and might lead to significant side effects without achieving adequate glucose lowering.
*A sodium-glucose cotransporter 2 inhibitor added to metformin*
- SGLT2 inhibitors promote glucose excretion in the urine and offer cardiovascular and renal benefits, but they are generally less potent in reducing HbA1c compared to insulin, especially in patients with severe hyperglycemia.
- While beneficial for some, they would not provide the rapid and substantial glucose reduction needed for a patient with an HbA1c of 11% and acute symptoms.
Question 69: A 63-year-old woman presents with dyspnea on exertion. She reports that she used to work in her garden without any symptoms, but recently she started to note dyspnea and fatigue after working for 20–30 minutes. She has type 2 diabetes mellitus diagnosed 2 years ago but she does not take any medications preferring natural remedies. She also has arterial hypertension and takes torsemide 20 mg daily. The weight is 88 kg and the height is 164 cm. The vital signs include: blood pressure is 140/85 mm Hg, heart rate is 90/min, respiratory rate is 14/min, and the temperature is 36.6℃ (97.9℉). Physical examination is remarkable for increased adiposity, pitting pedal edema, and present S3. Echocardiography shows a left ventricular ejection fraction of 51%. The combination of which of the following medications would be a proper addition to the patient’s therapy?
A. Metoprolol and indapamide
B. Enalapril and bisoprolol (Correct Answer)
C. Spironolactone and fosinopril
D. Indapamide and amlodipine
E. Valsartan and spironolactone
Explanation: ***Enalapril and bisoprolol***
- This patient presents with **heart failure with preserved ejection fraction (HFpEF)**, characterized by symptoms of heart failure (dyspnea, fatigue, edema, S3 sound) with an LVEF >50%. She also has **uncontrolled hypertension** (BP 140/85) and a **heart rate of 90/min**.
- **Important:** Unlike HFrEF, **ACE inhibitors and beta-blockers have NOT demonstrated mortality benefit in HFpEF** (CHARM-Preserved, PEP-CHF trials). However, they remain important for **blood pressure control** and **symptom management** in patients with HFpEF and comorbid hypertension.
- **Enalapril** (ACE inhibitor) helps control blood pressure through reduction of preload and afterload. **Bisoprolol** (beta-blocker) provides **heart rate control** (patient's HR is 90/min) and further blood pressure reduction. Both medications address her inadequately controlled hypertension while managing symptoms.
- **Note:** Current guidelines emphasize SGLT2 inhibitors as first-line therapy for HFpEF (not offered here), along with diuretics for volume management (patient is already on torsemide) and aggressive treatment of comorbidities like hypertension and diabetes.
*Metoprolol and indapamide*
- Metoprolol is a beta-blocker that could help with rate and blood pressure control. However, **indapamide is a thiazide-like diuretic** that is redundant since the patient is already on **torsemide** (a loop diuretic) for volume management.
- This combination lacks an **ACE inhibitor or ARB** for optimal blood pressure control and neurohormonal modulation, which is important even in HFpEF for managing hypertension and its consequences.
*Spironolactone and fosinopril*
- **Spironolactone** (mineralocorticoid receptor antagonist) showed modest benefit in reducing HF hospitalizations in the TOPCAT trial for HFpEF. **Fosinopril** is an ACE inhibitor appropriate for blood pressure control.
- However, the patient has a **heart rate of 90/min**, indicating need for **rate control** which neither spironolactone nor fosinopril provides. A **beta-blocker would be more appropriate** to address both rate control and blood pressure.
- Additionally, while spironolactone has some evidence in HFpEF, the combination with an ACE inhibitor **without rate control** is suboptimal for this patient's presentation.
*Indapamide and amlodipine*
- **Indapamide** (thiazide-like diuretic) is **redundant** since the patient is already on torsemide. **Amlodipine** (calcium channel blocker) is effective for hypertension but can cause **peripheral edema**, which this patient already has (pitting pedal edema).
- **Calcium channel blockers are not recommended in heart failure** due to lack of mortality benefit and potential to worsen fluid retention. This combination does not address the underlying HFpEF pathophysiology or provide optimal symptom management.
*Valsartan and spironolactone*
- **Valsartan** (ARB) is appropriate for blood pressure control and is an alternative to ACE inhibitors. **Spironolactone** has modest evidence for reducing hospitalizations in HFpEF (TOPCAT trial).
- However, similar to the fosinopril/spironolactone combination, this lacks a **beta-blocker for heart rate control** (patient's HR is 90/min). Rate control is important for optimizing diastolic filling time in HFpEF and controlling blood pressure.
- While this combination has theoretical benefits, **enalapril and bisoprolol** better addresses both blood pressure control and rate control simultaneously.
Question 70: A 58-year-old man is rushed to the ER in the middle of the night with severe chest pain. He arrives in the ER short of breath, sweating, and looking terrified. His blood pressure is noted to be 250/140, and he is immediately administered nitroprusside. His blood pressure is controlled, but he soon develops confusion and lactic acidosis. Which of the following best explains these findings?
A. Cyanide toxicity (Correct Answer)
B. Hypoventilation
C. Cough
D. Decreased intracranial pressure
E. Hyperkalemia
Explanation: ***Cyanide toxicity***
- **Nitroprusside** metabolizes into nitric oxide and five **cyanide ions**, which can overwhelm the body's detoxification capacity, especially in patients with prolonged infusion or impaired renal function.
- Symptoms such as **confusion** and **lactic acidosis** are classic signs of **cyanide toxicity**, resulting from inhibition of cellular respiration and oxygen utilization.
*Hypoventilation*
- While some medications can cause hypoventilation, **nitroprusside** primarily affects vascular smooth muscle and does not directly depress respiratory drive.
- The patient's **shortness of breath** initially was more likely due to a hypertensive emergency or underlying cardiac event, not hypoventilation due to nitroprusside.
*Cough*
- **Cough** is not a common side effect of **nitroprusside**; rather, it is often associated with ACE inhibitors or certain respiratory conditions.
- The acute presentation of this patient suggests a different etiology for any respiratory distress he might be experiencing.
*Decreased intracranial pressure*
- **Nitroprusside** is a potent vasodilator and can actually cause a **dose-dependent increase in intracranial pressure**, not a decrease, due to increased cerebral blood flow.
- This effect is particularly concerning in patients with pre-existing elevated ICP.
*Hyperkalemia*
- **Hyperkalemia** is not typically associated with **nitroprusside** administration.
- Medications like ACE inhibitors, ARBs, or potassium-sparing diuretics are more commonly linked to hyperkalemia.
